F5 Antibody

中文名稱：

F5兔多克隆抗體
貨號：

CSB-PA007929HA01HU
規格：

￥440
圖片：
Immunohistochemistry of paraffin-embedded human liver cancer using CSB-PA007929HA01HU at dilution of 1:100

Immunofluorescent analysis of HepG2 cells using CSB-PA007929HA01HU at dilution of 1:100 and Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L)
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) F5 Polyclonal antibody
Uniprot No.：

P12259
基因名：

F5
別名：

Activated protein C cofactor antibody; APC cofactor antibody; coagulation factor V (proaccelerin; labile factor) antibody; Coagulation factor V antibody; coagulation factor V jinjiang A2 domain antibody; Coagulation factor V light chain antibody; F5 antibody; FA5_HUMAN antibody; Factor V Leiden antibody; FactorV antibody; FVL antibody; Labile factor antibody; PCCF antibody; Proaccelerin antibody; proaccelerin; labile factor antibody; Protein C cofactor antibody; RPRGL1 antibody; THPH2 antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Coagulation factor V protein (1490-1614AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，F5 Antibody (CSB-PA007929HA01HU)，的標記方式是Non-conjugated。對于F5 Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA007929HB01HU	F5 Antibody, HRP conjugated	ELISA
FITC	CSB-PA007929HC01HU	F5 Antibody, FITC conjugated
Biotin	CSB-PA007929HD01HU	F5 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, IHC, IF

推薦稀釋比：

Application	Recommended Dilution
IHC	1:20-1:200
IF	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Central regulator of hemostasis. It serves as a critical cofactor for the prothrombinase activity of factor Xa that results in the activation of prothrombin to thrombin.
基因功能參考文獻：
1. factor V Leiden and MTHFR C677T polymorphisms were significantly associated with recurrent pregnancy loss (RPL) in Bosnian women... PMID: 29703881
2. study found the FVL A allele frequency and GA genotype are significantly more prevalent among patients with coronary artery disease (CAD) compared to controls and may be predisposing to CAD; further found that the FVL mutation is an independent risk factor whose effect is not modified by other risk factors; FV HR2 variation does not show any statistically significant association with CAD PMID: 29179580
3. suggesting that the FVL paradox is related to the carriership of one wild type and one mutated factor V allele PMID: 29320959
4. Review/Meta-analysis: Factor V G1691A single nucleotide gene polymorphism was associated with risk of ischemic stroke mainly in young adults. PMID: 29478939
5. Factor V Leiden mutation is associated with venous thromboembolism in cancer. PMID: 29775482
6. Human FVL carriers have a higher total sperm count than non-carriers, with an adjusted mean difference of 31 x 106 (95%CI 0.2-61.7; P = 0.048). PMID: 28927238
7. contribution of FVLeiden causing resistance to activated protein C in Indian population is not as strong as previously reported in Western countries PMID: 26699866
8. The frequencies of GA and AA genotypes and A allele of coagulation factor V (FV) 1691G>A polymorphism significantly increased in the lower extremity deep venous thrombosis (LDVT) group. Patients with LDVT carrying A allele (GA + AA) had both higher patency and recurrence rates than those carrying GG genotype. Coagulation factor V (FV) 1691G>A polymorphism may be associated with both the risk and prognosis of LDVT. PMID: 29851809
9. Factor V Leiden-mutations were found in 16.8% of patients with cerebral sinus venous thrombosis and in 17.8% of patients with arterial ischemic stroke, which was significantly more frequent than in controls at a rate of 4.95% (ORs: 3.89 and 4.16). PMID: 28869458
10. Double heterozygotes had a clinical presentation intermediate between FVL and prothrombin mutation single carriers. PMID: 28577389
11. genetic study of Factor V Leiden (G1691A) mutation in young ischemic strokes with large vessel disease in a South Indian population PMID: 28711293
12. results suggest that some SNPs of F5 and a high or low FV:C level might be associated with recurrent miscarriage PMID: 27655299
13. FVBonn induces hypercoagulability via a combination of increased activation/procoagulant activity, decreased susceptibility to Activated protein C-mediated inactivation, and slightly reduced APC cofactor activity PMID: 27090446
14. Heterozygous FV Leiden, homozygous PAI-1 4G/4G, heterozygous MTHFR C677T, homozygous MTHFR A1298C, as much as the combined thrombophilic genotypes MTHFR 677T + ACE Iota/D, MTHFR 677T/1298C + ACE D/D, ACE I/D + b-fibrinogen -455 G/A, FV HR2 + b-fibrinogen -455 G/A showed a correlation as risk factors for Recurrent pregnancy loss. PMID: 28603947
15. the signaling and anticoagulant functions of APC are in spatially and kinetically distinct compartments, and that it is possible to specifically inhibit the anticoagulant activity of APC. Targeting APC with a serpin is remarkably effective and may be safe for long-term prophylactic use in the treatment of hemophilia. PMID: 28632502
16. Cleavage of FV at Arg(1545) , which abolishes the anticoagulant properties of FV and commits FV to the procoagulant pathway, is inhibited by binding of the TFPIalpha C-terminus to the FV acidic region PMID: 27801970
17. The goal of this study was to evaluate the impact of EHR point-of-care tools on medical record documentation of genetic testing care processes for the common HFE mutations, a thrombophilia panel, and HLA-B27. PMID: 27362912
18. Aside from a higher venous thromboembolism (VTE) prevalence and modestly reduced VTE-free survival, VTE penetrance and phenotype severity did not differ significantly among homozygous vs. heterozygous carriers. PMID: 26970916
19. there is a synergistic effect of the FVL and rs4524 single nucleotide polymorphisms and active cancer on the risk of VTE. PMID: 27479824
20. Our finding that the C2-domain of FVIII can be replaced by that of FV without compromising FVIII activity may have translational implications. PMID: 28057741
21. These results demonstrate a new anticoagulant (cofactor) function of FV that targets the early phase of coagulation before prothrombinase assembly PMID: 28420729
22. There was an increased odds of stillbirth for maternal homozygous factor V Leiden mutation. PMID: 27131585
23. The Leiden mutation was significantly associated with recurrent pregnancy loss (p=0.017) PMID: 26564286
24. The present meta-analysis suggests that V Leiden G1691A mutation is not significantly associated with increased risk of sudden sensorineural hearing loss in Italian population. PMID: 26620341
25. Factor V Leiden was not associated with recurrent miscarriage during the first trimester of pregnancy in Brazilian women. PMID: 27525841
26. Gene polymorphisms F5 C>G (rs6427196) were not associated with height, weight, or morbid obesity among European subjects. PMID: 27999448
27. The carriage of mutant genotypes of FV 1691 G/A gene is a prognostic factor for rapid liver fibrosis progression in patients with Chronic hepatitis C. PMID: 27636933
28. Our data demonstrated a significantly increased risk of hemodialysis vascular access thrombosis in carriers of the mutant FV (G1691A and A4070G) polymorphisms (P< 0.05) PMID: 27004938
29. Desmopressin acetate has no effect on FV plasma concentration in patients with combined deficiency of factors V and VIII. PMID: 26599105
30. F5 rs6025 and F11 rs2289252 contributed to the risk of recurrent venous thromboembolism and the combination is of potential clinical relevance for risk prediction PMID: 26423325
31. Factor V (F5) c.1691G>A (Leiden) was present in 0.5% of 400 ischemic stroke patients in Sri Lanka. F5 mutation was present in a statistically significant number of patients with venous thrombosis (P = .005) compared to those with arterial thrombosis. PMID: 26522268
32. FVL has a modifying effect on PAI-1 polymorphism in relation to risk of VTE recurrence. PMID: 26245493
33. combination of FVL and MTHFR mutation related to the risk of recurrent fetal death and habitual abortion PMID: 25586317
34. Case Report: acquired FV inhibitor that developed in a patient after exposure to human thrombin used as a hemostatic agent during an otorhinolaryngology surgical procedure. PMID: 26270511
35. In the current study Factor V Leiden, prothrombin G20210A, and thrombospondin-1 polymorphisms showed no association with severity of hepatic fibrosis. PMID: 26768578
36. Chromosomal abnormalities and abnormalities in the genes related to thrombophilia such as FVL, MTHFR and PTm mutations may be considered as risk factors for RM [recurrent miscarriage] PMID: 26060483
37. Given the essential role of platelet-derived factor Va in clot formation, understanding the cellular and molecular mechanisms that regulate how platelets acquire this molecule will be important for the treatment of excessive bleeding or clotting PMID: 25800007
38. F5 polymorphisms are not significant in the susceptibility to femoral head osteonecrosis in the Korean population. PMID: 26130054
39. ). No significant difference was observed in the presence of FV 1691G/A and FII 20210G/A between any of the patients groups and the control group. PMID: 26261166
40. the diagnosis of an 'unaffected' foetus was offered. The child was subsequently followed up after delivery and was found to be normal for factor V levels with a normal genotype PMID: 26261171
41. Data (including data from case-control, genetic association studies) suggest that Factor V mutation Leiden is associated with significant genetic predisposition for venous thromboembolism (not thrombophilia) in pregnancy. [META-ANALYSIS, REVIEW] PMID: 26115054
42. C2491T FV mutation associated with ischaemic stroke risk in Morocco, is reported. PMID: 26174681
43. genetic association studies in population in Czech Republic: Data suggest point mutation in FV (Leiden) is associated with outcome in patients with hereditary thrombophilia/diabetes/limb ischemia following percutaneous transluminal angioplasty. PMID: 26247037
44. FVL mutation is a significant determinant of coronary artery disease risk. PMID: 24360889
45. Activated protein C has anti-inflammatory effects on human dendritic cells. PMID: 25891444
46. Polymorphisms in factor V and antithrombin III gene in recurrent pregnancy loss PMID: 25771983
47. presence of three novel variants in F5 gene in Chilean patients with activated protein C resistance; further studies are required to investigate the real contribution of these novel mutations to the APC resistance phenotype PMID: 25668227
48. FV Leiden is a genetically determined and thus disease-independent parameter, which is associated with venous thromboembolism in cancer patients and could therefore be used for individual risk assignment. PMID: 25381723
49. In mice, heterozygous FV Leiden carriers are protected from sepsis mortality after infection with clinically relevant human bacterial pathogens. PMID: 25690763
50. Our study does not support the notion that factor V HR2 haplotype might be a risk factor for thrombosis despite its high prevalence among patients with PE. PMID: 26717220
顯示更多

收起更多
相關疾病：

Factor V deficiency (FA5D); Thrombophilia due to activated protein C resistance (THPH2); Budd-Chiari syndrome (BDCHS); Ischemic stroke (ISCHSTR); Pregnancy loss, recurrent, 1 (RPRGL1)
亞細胞定位：

Secreted.
蛋白家族：

Multicopper oxidase family
組織特異性：

Plasma.
數據庫鏈接：

HGNC: 3542

OMIM: 188055

KEGG: hsa:2153

STRING: 9606.ENSP00000356771

UniGene: Hs.30054

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human